News
The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback